canertinib dihydrochloride has been researched along with chir-265 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (chir-265) | Trials (chir-265) | Recent Studies (post-2010) (chir-265) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 33 | 1 | 31 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | chir-265 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.6095 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.14 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.006 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.02 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0501 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.02 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.02 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.66 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and chir-265
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |